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Background: Post-thymectomy pain in myasthenia gravis (MG) patients can inhibit breathing and coughing.
Inappropriate usage of analgesics may exacerbate respiratory inhibition and even cause myasthenic crisis.
Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) that is commonly used to control moderate
postoperative pain and is not associated with respiratory inhibition. We hypothesized that flurbiprofen may
provide post-thymectomy pain relief without increasing the risk of complications in MG patients.
Methods: Two hundred MG patients underwent extended thymectomy from March 2006 to December 2010 and
were randomly allocated to a flurbiprofen group (110 patients, 50 mg intravenous flurbiprofen axetil) or a control
group (90 patients, 100 mg intramuscular tramadol) as postoperative analgesia. Visual analog scale (VAS) pain score,
heart rate, blood pressure, respiratory rate, pulse oximetry (SpO2), and adverse effects were recorded before and up
to 24 h after drug administration.
Results: There were no significant differences in the preoperative clinical characteristics of the flurbiprofen and
control (tramadol) groups. Both flurbiprofen and tramadol significantly alleviated post-thymectomy pain (p< 0.05 for
both), but patients in flurbiprofen group had significantly lower VAS pain scores at 0.5 h, 2 h, 4 h, and 8 h after
surgery (p< 0.05 for all times). There were no significant post-thymectomy changes of heart rate, respiratory rate,
mean arterial blood pressure, or SpO2 in either group at all time points.
Conclusions: Post-thymectomy intravenous administration of flurbiprofen axetil provides safe and effective
analgesia for MG patients.
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Myasthenia gravis (MG) is an autoimmune disorder
characterized by progressive muscle fatigue due to altera-
tions of the postsynaptic neuromuscular junction. Most
patients also experience abnormalities of the thymus
gland, such as thymoma or benign thymus hyperplasia
[1,2]. Thymectomy in the early stages of MG often
improves the overall prognosis [3,4]. The extended trans-
sternal thymectomy is believed as a routine and* Correspondence: chenzhenguang@yahoo.com; luohhzm@163.com
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reproduction in any medium, provided the orcomplete surgical dissection procedure [5-9], and video-
assisted thoracic surgery (VATS) thymectomy and
robotic-aided video-assisted thoracoscopic thymectomy
are continually being developed [10,11]. Based on series
of 5-year follow-up data, combined cervical and bilateral
videoscopic thymectomy and the combined transcervi-
cal–transsternal thymectomy have 51 and 50%, respect-
ively, remission rates at that interval. Similarly, extended
transsternal thymectomy has 40% remission rate and a
high percentage of patients with ocular or mild pre-
operative MG manifestations [12-14]. It suggests that at
the extended or combined transcervical transsternal
thymectomy have the better remission rates and the out-
comes of different minimally invasive approach are still
in the investigative phase. Considering that the extended
transsternal thymectomy is conventional until now,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cant problem in MG patients who have undergone thym-
ectomy via median sternotomy incision [15,16]. Surgical
pain following thymectomy may disrupt breathing and
inhibit coughing, and thus may hamper patient recovery
and even lead to myasthenic crisis [16,17].
The choice of analgesic agent and route of administra-
tion are important because post-thymectomy pain may
compromise pulmonary function, and hypersensitivity to
an analgesic agent may induce respiratory depression.
Previous research reported good results with high thor-
acic (C7T1-3) epidural combinations of bupivacaine and
morphine in a small number of patients, but the paucity
of such cases and the technical difficulties associated
with administration of thoracic epidural analgesia have
prevented acceptance of this technique [18]. However,
there are few established analgesics for treatment of
post-thymectomy pain in these patients. Traditional
analgesics, such as tramadol, may cause severe nausea
and vomiting, and inhibit respiration [19,20]. All analge-
sics must be used with care in post-thymectomy patients
with MG [21].
Non-steroidal anti-inflammatory drugs (NSAIDs) also
provide relief from pain after different types of surgery
[22,23]. Flurbiprofen is an NSAID that can safely and ef-
fectively control moderate postoperative pain [23,24]. A
recent Cochrane review reported that oral flurbiprofen at
a dose of 50 mg or 100 mg provided at least 50% pain re-
lief in 65% to 70% of postoperative patients and only had
a weak inhibitory effect on respiration [25]. Systemic
flurbiprofen given as treatment for postoperative pain
following thoracotomy reduces serum levels of IL-6 and
CRP and appears to contribute to the attenuation of the
postoperative inflammatory response and prevent post-
operative pain [26]. However, the effect of intravenous
flurbiprofen on post-thymectomy pain relief in patients
with MG has not been established.
In the present study, we investigated the effect of intra-
venous flurbiprofen on relief from post-thymectomy pain
in patients with MG.
Methods
Patient data
MG patients who underwent extended thymectomy in
the Department of Thoracic Surgery of the First Affiliated
Hospital of Sun Yat-sen University (Guangzhou, China)
from March 2007 to December 2010 were enrolled. Clin-
ical information was obtained by review of the preo-
perative and perioperative medical records. MG was
diagnosed based on patient history, clinical symptoms,
chest computed tomography, positive response to the
edrophonium chloride test, and positive findings by
single-fiber electromyography and was staged by criteria
of the MG Foundation of America [27,28].Anticholinesterase agents were administered by neurology
consultants, and none of the patients received immuno-
suppressive agents preoperatively. All patients underwent
extended thymectomy via median sternotomy followed by
standard wound closure, as described previously [29].
Patients were randomly assigned to the flurbiprofen group
(50 mg intravenous flurbiprofen axetil diluted in 0.9% so-
dium chloride, completed within 1 h) or to the control
group (100 mg intramuscular tramadol) for postoperative
analgesia. The duration of surgery, time of chest drainage,
MGFA stage at 72 h after operation, presence of myasthe-
nia crisis, and adverse reactions were recorded. The hos-
pital ethics committee approved the study protocol (No.
2012–038).
Evaluation of the postoperative pain
A self-reported visual analog scale (VAS) was used to
evaluate postoperative pain, in which 0 indicated “no
pain”, 1 to 3 indicated “mild pain”, 4 to 6 indicated
“moderate pain”, and 7 to 10 indicated “severe pain”.
The severity of nausea and vomiting was recorded with a
four-point scale in which 0 indicated “no nausea or
vomiting”, 1 indicated “no nausea at rest or nausea with
mild vomiting on exertion”, 2 indicated “intermittent
nausea at rest or nausea with moderate vomiting on
exertion, and 3 indicated “persistent nausea at rest or
severe nausea with severe vomiting on exertion”. Mean
arterial blood pressure, heart rate, respiratory rate, and
SpO2, were recorded before surgery and at 0.5 h, 2 h,
4 h, 8 h, and 24 h after administration of analgesics.
A myasthenic crisis was defined as respiratory failure
caused by respiratory muscle weakness. Adverse events,
including gastrointestinal bleeding, ulcers, dizziness,
lethargy, flushing, itching, urinary retention, constipa-
tion, respiratory inhibition, abnormal bleeding, were also
recorded. Nausea and vomiting were treated with 10 mg
of intramuscular metoclopramide, and headache was
treated with 60 mg of intramuscular rotundine.
Statistical analysis
All statistical calculations were performed using SPSS
ver. 14.0 (Chicago, Illinois, USA). All data are given as
means ± standard deviations. The chi-square test and the
Mann–Whitney test were used for comparisons, as
appropriate. For all tests, a two-sided p-value less than
0.05 was considered significant. Hazard ratios (HR) and
95% confidence intervals (CIs) were calculated to assess
the significance of differences.
Results
Basic clinical information
Our study cohort consisted of 200 patients with non-
thymomatous MG who were treated by extended thym-
ectomy (Table 1). There were 98 males and 102 females,
Table 1 Clinical and demographic characteristics of the flurbiprofen and control (tramadol) groups
Characteristic Flurbiprofen Control (tramadol) p value*
n 110 90
Male/female, n (%) 59 (53.6)/51 (46.4) 43 (47.8)/47 (52.2) 0.504
Age at surgery, years 31.1 ± 11.8 30.3 ± 13.1 0.691
Mean disease duration, years 1.5 ± 0.8 1.8 ± 0.9 0.401
With/without medulla symptoms, n (%) 17 (15.5)/93 (84.5) 15 (16.7)/75 (83.3) 0.816
MGFA stage, n (%) 0.954
I 46 (41.8) 38 (42.2)
IIa 41 (37.3) 33 (36.7)
IIb 17 (15.5) 15 (16.7)
IIIa 6 (5.45) 4 (4.44)
Time of operation (min) 111.8 ± 25.4 116.4 ± 24.0 0.843
Time of chest drainage (d) 2.7 ± 0.5 2.4 ± 0.8 0.927
Myasthenia crisis 4 (3.6) 3 (3.3) 0.911
MGFA stage at 72 h after operation, n (%) 0.931
I 47 (42.7) 39 (43.3)
IIa 42 (38.2) 33 (36.7)
IIb 15 (13.6) 14 (15.6)
IIIa 6 (5.45) 4 (4.44)
Adverse reactions
Nausea and vomiting 14 (12.7) 26 (28.9) 0.021
Headache 5 (4.5) 9 (10.0) 0.162
Facial flushing 3 (2.7) 4 (4.4) 0.526
Values are given as median ± SD or (percentage). MGFA, Myasthenia Gravis Foundation Association.
* p-values were calculated by the χ2 test.
Figure 1 Comparison of visual analog pain scores in the
flurbiprofen and control groups. An asterisk indicates a significant
difference (p< 0.05).
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median, 27.2 years), and the mean duration of symptoms
was 1.72 ± 0.21 years (range, 0.5-23 years; median, 1 year).
A total of 84 patients were MGFA stage I, 74 were stage
IIa, 32 were stage IIb, and 10 were stage IIIa.
A total of 110 patients were randomized to the flurbipro-
fen group and 90 patients to the control (tramadol) group.
After surgery, seven cases of myasthenic crisis were
recorded, with four cases in the flurbiprofen group (two
cases with stage IIb and two cases with stage IIIa), and three
cases in the control group (one case with stage IIb and two
cases with stage IIIa). Nausea and vomiting were significantly
more common in the control group (28.9% vs. 12.7%,
p=0.021), but there were no other significant differences be-
tween the flurbiprofen and control groups.
Assessment of postoperative pain
Before analgesic administration, patients in both groups
complained of wound pain, difficulty with deep breath-
ing, and coughing, and all patients had VAS pain
scores of 7 or higher. Our results indicate that both
drugs significantly alleviated postoperative pain and that
the mean VAS pain score was significantly lower in theflurbiprofen group at 0.5 h, 2 h, 4 h, and 8 h after sur-
gery (p < 0.05) (Figure 1). There were no differences be-
tween the two groups in heart rate (Figure 2A),
respiratory rate (Figure 2B), mean arterial blood pressure
(Figure 2C), or oxygen saturation (Figure 2D) for up to
24 h after surgery.
Figure 2 A, Comparison of heart beat variation in the flurbiprofen and control groups; B, Comparison of respiratory rate variation in
the flurbiprofen and control groups; C, Comparison of mean arterial blood pressure variation in the flurbiprofen and control groups; D,
Comparison of variation in blood oxygen saturation in the flurbiprofen and control groups.
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Nausea and vomiting were significantly more common
in the control group than in the flurbiprofen group
(12.7% vs. 28.9%, p= 0.021, Table 1). At 30 min after ini-
tiation of analgesia, there were no adverse reactions in
either group. In the flurbiprofen group, there 14 cases of
nausea and vomiting at 2 h, (6 cases with scores of 3, 8
cases with scores of 2), 9 cases of nausea and vomiting at
4 h, and 5 cases of nausea and vomiting at 8 h. In
the control group, there were 26 cases of nausea and
vomiting at 2 h (12 cases with scores of 3, 14 cases with
scores of 2), and 16 cases of nausea and vomiting at 4 h
and 8 h.
At 2 h after drug injection, five cases in flurbiprofen
group and nine cases in control group had headaches,
but all of these patients experienced remission at 4 h. Re-
markably, three cases in the flurbiprofen group and four
cases in the control (tramadol) group had facial flushing
at 2 h after drug injection, and these symptoms remained
for 24 h in all patients.
Discussion
Extended thymectomy is recognized worldwide as an im-
portant technique to manage myasthenia gravis, and me-
dian sternotomy is the major surgical method [1,3,27].
The injury caused by this surgery is considerable, becausethe pleura are often damaged during resection of
anterior mediastinal fat tissue. Surgery may lead to
hemothorax or pleural effusion that can affect pulmonary
re-expansion. Coughing, sputum expulsion, and initiation
of deep breathing are important measures that promote
lung re-expansion and reduce the risk of pulmonary
infection. The surgical pain of such patients typically has
medium-to-high intensity, and may inhibit breathing,
coughing, and sputum expulsion, thereby disrupting
postoperative recovery, increasing the risk of pulmonary
atelectasis and infection, and even induce myasthenic
crisis [30]. Our previous study of MG patients demon-
strated that the serum concentration of immunoglobulin
G was high after thymectomy [31]. Another report
showed that the levels of serum CRP, IL-6, and
TNF-α were elevated after thoracotomy [26]. Together,
these findings indicate significant inflammation after
thymectomy, suggesting that an anti-inflammatory agent
such as flurbiprofen may be effective in reducing this
inflammation.
Common analgesics, such as tramadol and adolens, are
often not recommended for MG patients because they
can depress respiration and are associated adverse effects
(nausea, vomiting, irritability) that can increase the risk
of a myasthenic crisis or worsen postoperative condi-
tions. Therefore, an effective analgesic is needed that
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inhibit the respiratory muscles.
Flurbiprofen axetil (2-[3-fluoro-4-biphenyl] propanoic
acid) is an NSAID of the propionic acid class and tablets
are approved for relief of pain from rheumatoid arthritis
and osteoarthritis [32]. Intravenous flurbiprofen axetil is
provided as 50 mg ampoules and selectively accumulates
at the surgical incision and inflammation sites after
administration. Flurbiprofen axetil is mostly metabolized
into flurbiprofen by hydrolysis and its analgesic effect is
believed to result from the reversible inhibition of
cyclooxygenase and peripheral inhibition of prostaglan-
din synthesis. Analgesia has been reported to last for up
to 24 h after intravenous administration [33]. During
postoperative pain management with flurbiprofen,
patients must be monitored for side effects, especially
gastrointestinal effects, as with all NSAIDs [2,34]. Pre-
vious studies have reported that use of flurbiprofen for
postoperative analgesia in anesthesia, general surgery,
obstetrics and gynecology, and orthopedics was effective
and safe, had little effect on respiration, and prolonged
the duration of analgesia [35-38]. However, there have
been no reports on the use of flurbiprofen following
thoracic surgery or in patients with MG following
extended thymectomy.
Our results indicate that intravenous flurbiprofen axetil
can effectively reduce post-thymectomy pain without dis-
ruption of respiratory rate, heart rate, or blood pressure.
The analgesic effect lasted for up to 24 h for most
patients. There was no significant difference in the inci-
dence of myasthenic crisis in the flurbiprofen and con-
trol groups and there were fewer adverse effects in the
flurbiprofen group. The most common adverse effects
following flurbiprofen axetil were headache, vomiting,
and flushing. Mild symptoms resolved by themselves
within 3 days, and there were more cases of adverse
reactions in the control group. Slow intravenous admin-
istration of flurbiprofen allows immediate withdrawal if
respiratory inhibition occurs and provides an extended
duration of analgesia.
This study confirms that flurbiprofen axetil is a safe
and effective analgesic for post-thymectomy patients
with MG and that it is associated with a lower incidence
of adverse reactions than tramadol. Thus, slow intraven-
ous administration of flurbiprofen axetil is safe for clin-
ical use and is not associated with respiratory inhibition.
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